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Our purpose is to investigate the feasibility of imaging tumor me-
tabolism in breast cancer patients using 13C magnetic resonance
spectroscopic imaging (MRSI) of hyperpolarized 13C label exchange
between injected [1-13C]pyruvate and the endogenous tumor lac-
tate pool. Treatment-naïve breast cancer patients were recruited:
four triple-negative grade 3 cancers; two invasive ductal carcino-
mas that were estrogen and progesterone receptor-positive
(ER/PR+) and HER2/neu-negative (HER2−), one grade 2 and one grade
3; and one grade 2 ER/PR+ HER2− invasive lobular carcinoma (ILC).
Dynamic 13C MRSI was performed following injection of hyperpolar-
ized [1-13C]pyruvate. Expression of lactate dehydrogenase A (LDHA),
which catalyzes 13C label exchange between pyruvate and lactate,
hypoxia-inducible factor-1 (HIF1α), and the monocarboxylate trans-
porters MCT1 and MCT4 were quantified using immunohistochemis-
try and RNA sequencing. We have demonstrated the feasibility and
safety of hyperpolarized 13C MRI in early breast cancer. Both intertu-
moral and intratumoral heterogeneity of the hyperpolarized pyru-
vate and lactate signals were observed. The lactate-to-pyruvate
signal ratio (LAC/PYR) ranged from 0.021 to 0.473 across the tumor
subtypes (mean ± SD: 0.145 ± 0.164), and a lactate signal was ob-
served in all of the grade 3 tumors. The LAC/PYR was significantly
correlated with tumor volume (R = 0.903, P = 0.005) and MCT 1 (R =
0.85, P= 0.032) and HIF1α expression (R= 0.83, P= 0.043). Imaging of
hyperpolarized [1-13C]pyruvate metabolism in breast cancer is feasi-
ble and demonstrated significant intertumoral and intratumoral met-
abolic heterogeneity, where lactate labeling correlated with MCT1
expression and hypoxia.
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breast cancer
Breast cancer accounts for ∼25% of all cancer cases and is theleading cause of cancer death among women worldwide (1).
Breast tumors show considerable heterogeneity, both within and
between tumors, which partly accounts for the variable clinical
course of the disease and response to treatment. Some of this
heterogeneity is captured by hormone receptor expression and
HER2 amplification/overexpression, which can be used to guide
targeted treatment options. Genomic and transcriptional infor-
mation can also indicate prognosis and may be used to select
therapy pathways (2). Alterations in tumor metabolic pathways,
which drive tumor growth, can influence treatment response but
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be used for metabolic imaging of breast cancer patients in the
clinic, creating possibilities for noninvasive cancer monitoring in
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are not easily assessed in a routine clinical setting (3, 4). A clinical
tool that measures spatial and temporal variations in tumor
metabolism may further stratify patients in ways that are
complementary to histological and molecular profiling.
A major metabolic change in most cancer types is a switch to
aerobic glycolysis, known as the Warburg effect, which results in
increased lactate formation (5, 6). Hyperpolarized 13C MRI (HP
13C MRI), which increases the MRI signal acquired from 13C-
labeled substrates by more than 10,000-fold (7), is an emerging
clinical tool that can be used to probe this altered metabolism.
The most widely used hyperpolarized 13C-labeled substrate is
[1-13C]pyruvate, which is the product of glycolysis, and lies at the
intersection of several key metabolic pathways (8). Pyruvate is
reduced to lactate in the reaction catalyzed by lactate dehydro-
genase (LDH), which, in tumors, is predominantly the A isoform
(LDHA) (9). The massive gain in sensitivity afforded by hyper-
polarization means that the spatial distribution of intravenous
(i.v.) injected hyperpolarized 13C-pyruvate and the hyperpolarized
13C-lactate formed from it, can be imaged in real time (10).
Preclinical studies have shown that the tumor metabolic phe-
notype revealed by hyperpolarized 13C-lactate labeling can re-
flect disease aggressiveness (11) and provide rapid assessment of
treatment response, with multiple studies demonstrating an early
reduction in 13C-lactate labeling following therapy (12, 13). MRI
of hyperpolarized 13C-pyruvate metabolism has translated into
the clinic with lactate labeling demonstrated in prostate cancer
and brain tumors and preliminary evidence showing that it can
be used for treatment response assessment in prostate cancer (7,
14, 15). The latter studies suggest that the technique could also
be used to monitor the response of breast cancer patients to
neoadjuvant treatment (NAT), which is used increasingly in
routine patient management. NAT can be used to downstage the
tumor, permitting breast-conserving surgery, improving opera-
bility, and allowing direct response assessment in situ. A com-
plete pathological response (pCR) at surgery indicates a better
prognosis, especially in estrogen receptor-negative breast cancer
(16–19). Identifying effective treatments on an individual patient
basis is essential to reduce both morbidity and cost, as ineffective
NAT increases the time during which patients harbor chemo-
resistant tumor cells, thus increasing the risk of metastatic spread
(20). Despite the increasing use of advanced multiparametric
MRI in breast cancer patients undergoing NAT, there is an unmet
need to develop more-specific and sensitive treatment response
biomarkers to differentiate responders and nonresponders at an
early time point. The aims of this study were, firstly, to demon-
strate the feasibility of translating this imaging technique into the
clinical breast cancer field; secondly, to metabolically phenotype
breast cancers and evaluate which subtypes are most suitable for
response assessment using HP 13C MRI; and. thirdly, to correlate
lactate labeling with biological factors that may determine this
labeling, such as expression of the monocarboxylate transporters,
LDH, and markers of hypoxia and vascularity.
Methods
Patient Recruitment. Local research ethics committee approval was obtained
for this prospective study (National Research Ethics Service Committee East
of England, Cambridge South, Research Ethics Committee number 15/EE/
0378; National Institute for Health Research [NIHR] portfolio number 30388).
Seven women diagnosed with invasive carcinoma of the breast measuring at
least 1.5 cm in maximum diameter on ultrasound or mammogram were
consented between November 2016 and June 2018.
Proton MRI. Patients were imaged in a clinical 3T scanner (MR750; GE
Healthcare). The MRI system inbuilt 1H body coil was used to acquire three-
dimensional (3D) fast gradient echo scout images and, subsequently, T1-
weighted axial and coronal fast spoiled gradient echo images, which were
used to plan the 13C MRI. Following 13C MRI, diagnostic quality proton breast
imaging was undertaken in the prone position in a dedicated eight-channel
phased array receive-only breast coil (SI Appendix, Methods). For dynamic
contrast-enhanced (DCE) MRI, a 3D fast spoiled gradient echo sequence with
k-space data sharing was used (volume image breast assessment–time-
resolved imaging of contrast kinetics [VIBRANT-TRICKS]) as described
previously (21, 22) and reconstructed using an in-plane voxel-size of 0.68 ×
0.68 mm (slice thickness = 1.4 mm). Gadobutrol (Gadovist; Bayer, Schering)
was injected at 0.1 mmol/kg body weight and a flow rate of 3.0 mL/s fol-
lowed by a 25-mL saline flush. In total, 48 VIBRANT-TRICKS volumes were
acquired, over 8 min with a temporal resolution of 9.4 s. Contrast agent
injection was started between phases 2 and 3.
Preparation and Injection of 13C-Pyruvate. Hyperpolarization of samples con-
taining 1.47 g of [1-13C]pyruvic acid (Sigma Aldrich) and 15 mM electron
paramagnetic agent (EPA; Syncom) was performed in a clinical hyperpolarizer
(SPINlab; 5T Research Circle Technology) by microwave irradiation at 139 GHz
at ∼0.8 K for ∼3 h followed by rapid dissolution in 38mL of superheated sterile
water and filtration to remove EPA to a concentration below ≤3 μM. The
filtered formulation was neutralized with a buffer solution (SI Appendix,
Methods). Sample pH, temperature, pyruvate and EPA concentrations, po-
larization, and volume were measured by the SPINlab quality control (QC)
module to ensure appropriate QC criteria were obtained. Then 0.4 mL/kg of
∼250 mM hyperpolarized pyruvate solution was injected at 5 mL/s using a
power injector (Medrad) followed by a saline flush of 25 mL.
Carbon-13 MRI. A dedicated eight-channel 13C breast coil (Rapid Biomedical)
was used. A 13C-labeled 8 M urea sample (Sigma-Aldrich), positioned adja-
cent to the tumor-containing breast, was used to set the 13C transmit gain
and center frequency. Images were acquired using a dynamic coronal Iter-
ative Decomposition with Echo Asymmetry and Least squares estimation
(IDEAL) spiral chemical shift imaging (CSI) sequence (SI Appendix, Methods
and Table S1) (23). IDEAL spiral imaging data were reconstructed in MATLAB
R2018b (The MathWorks, Inc.). Complex imaging data from the eight breast
coil channels were combined as the square root of the sum of squares, with
signal from each channel weighted by the maximal signal-to-noise ratio
(SNR) of pyruvate. For analysis of metabolite ratios integrated over time, the
complex data were summed over all time points prior to coil combination to
minimize noise propagation. Images at the pyruvate, pyruvate hydrate,
lactate, alanine, and bicarbonate resonance frequencies were reconstructed
with an in-plane voxel size of 1.6 × 1.6 to 1.9 × 1.9 mm2 and a slice thickness
of 30 mm.
Tumor regions of interest (ROIs) were generated by thresholding the sum
of the summed lactate and pyruvate signals using a MATLAB program de-
veloped in-house. The threshold was chosen for each tumor individually so
that, when comparing thresholded 13C images and the DCE images, the di-
ameter of the ROI on the 13C images matched the maximum diameter of
the tumor on the coronal DCE images at peak enhancement. This semi-
automated approach was validated by comparing the results with those
obtained using ROIs drawn manually. There was a good correlation between
the lactate-to-pyruvate signal ratio (LAC/PYR) based on manual and
thresholded ROIs (SI Appendix, Fig. S1). There were no significant differences
between ROIs drawn in a semiautomated fashion and those drawn manually
for LAC/PYR (P = 0.711), summed lactate SNR (SNRLAC) (P = 0.107), and
summed pyruvate SNR (SNRPYR) (P = 0.097). To avoid potential bias in-
troduced by drawing ROIs manually, the semiautomated thresholding ap-
proach was used for further analyses in this study. Estimation of noise (mean
and SD) was performed using entire bicarbonate images, summed over the
time course (or pyruvate hydrate, if there were visible artifacts in the bi-
carbonate image). The noise distribution in images of the different indi-
vidual metabolites was expected to be the same, since all of the images were
calculated from the same underlying set of multi-echo time data, which was
confirmed empirically. Noise was best characterized from an entire image
where spiral acquisition artifacts were absent. To generate the SNR for py-
ruvate and lactate (SNRmetabolite) within each tumor, the following formula
was used:
SNRmetabolite   =  
mean  SIROI   tumor −mean  SInoise
ﬃﬃﬃ
2
p
  SDðSInoiseÞ
.
Mean SIROI tumor is the mean signal intensity in the tumor ROI; mean and SD
of SInoise were computed from the entire noise image series as described
above. The factor of √2 accounts for the narrowed Rayleigh distribution of
magnitude noise, with an approximate adjustment for the use of multiple
receivers (24, 25). The summed metabolite SNR over the entire image time
course is referred to as summed SNRPYR and summed SNRLAC. By dividing the
latter by the former, the [1-13C]lactate/[1-13C]pyruvate SNR ratio (LAC/PYR)
was calculated. As an alternative metric for assessing tumor metabolism of
Gallagher et al. PNAS | January 28, 2020 | vol. 117 | no. 4 | 2093
M
ED
IC
A
L
SC
IE
N
CE
S
[1-13C]pyruvate, the forward exchange rate constant (kPL) from the most
metabolically active voxel within each tumor was calculated, which was
determined as the voxel with the highest time-averaged lactate signal. This
approach was taken to maximize SNR, which is crucial for modeling of this
rate constant. These results were compared with the calculated LAC/PYR (SI
Appendix, Fig. S2). Based on the high variance of the fits of kPL in tumors
that had low summed SNRLAC, the LAC/PYR was chosen as a more robust
measure of pyruvate to lactate conversion.
DCE-MRI Analysis. In-house−developed MATLAB software was used to gen-
erate B1 maps. MIStar (Apollo Medical Imaging) was used to generate B1-
corrected T1 maps, to perform motion correction of the DCE-MRI data using
a 3D affine model, and for pharmacokinetic modeling using the standard
Tofts model (26). Tumor ROIs were drawn on the DCE-MRI data by a con-
sultant radiologist specialized in breast imaging with 10 y of experience
(V8.5.2 Pixmeo SARL; OsiriX). These ROIs were used to calculate tumor vol-
umes and to extract voxel-wise pharmacokinetic parameters (Ktrans, kep, ve,
and iAUC90) using in-house software written in MATLAB. Only voxels with
an adequate goodness of fit were included in the analyses.
Immunohistochemistry and Quantification of Monocarboxylate Transporters 1
and 4. For six patients, immunohistochemical (IHC) staining for the mono-
carboxylate transporters 1 and 4 (MCT1 and MCT4) was performed on
formalin-fixed, paraffin-embedded tumor blocks using Leica’s Polymer Re-
fine Detection System (DS9800) in combination with their Bond automated
system (Leica Biosystems Newcastle Ltd) (SI Appendix, Methods). Insufficient
tissue was available for analysis in one patient.
HALO v2.2.1870.15 (Indica Labs) and the area quantification v1 module
were used for automated analysis of scanned sections (optical densities are
provided in SI Appendix, Methods). Areas of weak, moderate, and strong
staining were summed and divided by the total tissue area to obtain the
percentage of positive tissue for MCT1 and MCT4 expression.
RNA Sequencing. RNA from frozen tumor tissue sections from six patients was
extracted using the QIAGEN miRNeasy Mini Kit (catalog no. 217004; QIAGEN;
details in SI Appendix, Methods). RNA quantification was performed using
Nanodrop technology (ThermoFisher Scientific). Assessment of the RNA in-
tegrity number was performed using a high-sensitivity RNA assay and a 2100
Bioanalyzer (Agilent Technologies).
RNA sequencing libraries were constructed using the TruSeq Stranded
Total RNA Gold library preparation kit (Illumina). The libraries were se-
quenced as paired-end reads (2 × 75 cycles) on an HiSeq2500 platform to give
a mean coverage of ×150. Postprocessing of the gene count data included
normalization, scaling, and the correction of library preparation effects
(details provided in SI Appendix, Methods).
Statistical Analysis. The lactate signal is likely to be dominated by the in-
tracellular compartment, particularly at early time points, whereas experi-
ments in vitro and in vivo (27–29) have shown that, at later time points, there
is substantial export of hyperpolarized 13C-labeled lactate into the extra-
cellular space. The pyruvate signal is derived mainly from the extracellular
pool, which includes intravascular pyruvate. Therefore, the summed SNRLAC
lactate signal from the tumor and the LAC/PYR are likely to reflect vascular
delivery of pyruvate, expression of the transporters mediating cellular py-
ruvate uptake (MCT1 and MCT4), and expression of LDHA, which catalyzes
exchange of the hyperpolarized 13C label between pyruvate and lactate. The
correlation of LAC/PYR, summed pyruvate signal (SNRPYR), and summed
lactate signal (SNRLAC) with tumor volume and IHC markers of hypoxia
(hypoxia-inducible factor 1-alpha [HIF1α]) were analyzed to assess the con-
tributions of hypoxia, pyruvate uptake, and metabolism to the observed
hyperpolarized 13C signals.
Statistical analyses were performed using R (version 3.4.0; R Foundation).
Normal distribution of the data was assessed using the Shapiro−Wilk test for
normality (threshold P ≥ 0.05). Correlations were assessed using Spearman’s
rank correlation test including the rank correlation coefficient (rho) when
data of at least one variable were nonnormal, and Pearson’s correlation
including the correlation coefficient R for data with normal distribution.
Differences between measurements based on manually drawn versus
thresholded ROIs were compared using Student’s t test for paired samples.
All statistical tests were two-sided. P values below 0.05 were considered
significant. No multiple testing correction was applied: Significant tests
should be interpreted as exploratory rather than confirmatory.
Data Availability. Transcriptomic data are deposited at the European
Genome-phenome Archive (EGA ID EGAS00001004118; https://www.ebi.ac.uk/
ega/studies/EGAS00001004118). Imaging raw data, and MATLAB scripts for
data in this manuscript can be obtained from radiology-13c-mri-breast@lists.
cam.ac.uk.
Results
The feasibility of using HP 13C MRI in breast cancer was demon-
strated in seven patients with a histopathological diagnosis of the
disease. These included one grade 2 (G2) invasive lobular carci-
noma (ILC), which was estrogen and progesterone receptorpositive
(ER/PR+) and HER2/neu-negative (HER2−); two invasive
carcinomas of no specific type (IC NST), which were ER/PR+
Fig. 1. Spectra and images from the patient cohort. (Top) Spectra from a coronal dynamic IDEAL spiral CSI slice covering each tumor; the spectra have been
summed over all 15 time points. (Bottom) Axial slices from the equivalent DCE-MRI data at the time point of maximum tumor enhancement. Abbreviations:
ppm, parts per million; ER, estrogen receptor; PR, progesterone receptor; HER2, HER2/neu.
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HER2− (one G2 and one G3); and four IC NST ER/PR−HER2−
G3 (triple-negative breast cancer [TNBC]; ER and PR negativity
defined as Allred score 0 to 3) (Fig. 1). Patient characteristics
(age, body mass index, breast parenchymal density) are shown in
SI Appendix, Table S2. No adverse effects were observed when
the patients were monitored for 1.5 h after injection of the
hyperpolarized agent. In all patients, HP 13C-lactate signal was
observed exclusively in the tumors but not in other areas of the
breast. Fibroglandular breast tissue demonstrated low HP 13C-
pyruvate signal in some patients, whereas adipose breast tissue
showed no signal. No other metabolite signals were observed in
breast tissue.
Intratumoral and Intertumoral Metabolic Heterogeneity. Intertu-
moral metabolic heterogeneity was observed with variation in the
summed LAC/PYR, summed SNRPYR, and summed SNRLAC.
The LAC/PYR ranged from 0.021 to 0.473 (mean ± SD, 0.145 ±
0.164), summed SNRPYR ranged from 6.2 to 74.3 (43.8 ± 25.8),
and summed SNRLAC ranged from −0.1 to 22.3 (6.5 ± 7.8) (Fig.
2). Hyperpolarized lactate signal was observed in all of the G3
tumors (TNBC and IC NST). There was no discernable lactate
signal in the two G2 tumors despite detectable pyruvate in all
seven tumors (Fig. 1). In addition, there was significant variation
in the LAC/PYR and summed SNRLAC within the TNBC sub-
group (ranges 0.031 to 0.473 and 1.1 to 22.3, respectively).
Fig. 2. Correlation of hyperpolarized 13C MRI data with tumor volume and expression of the MCT1 and HIF1α. (A) Each patient is represented by an indi-
vidual point, with the size of each circle proportional to the respective tumor size. (B and C) Correlation of LAC/PYR and summed SNRLAC with tumor volume.
(D−G) Correlation of LAC/PYR and summed SNRLAC with expression of MCT1, determined by both (D and E) IHC and (F and G) RNA sequencing. (H and I)
Correlation of LAC/PYR and summed SNRLAC with expression of HIF1α determined by RNA sequencing. Abbreviations: IHC [% pos tissue], percentage of
formalin fixed paraffin embedded tissue positive for IHC staining; RNAseq, normalized expression based on RNA sequencing.
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Intratumoral metabolic heterogeneity was observed in the largest
TNBC. The summed SNRLAC and summed SNRPYR were higher
in the tumor periphery than in the tumor core, which was similar
to the pattern of rim-like contrast enhancement on DCE-MRI,
suggesting that the rate of pyruvate delivery to the tumor has a
significant influence on lactate labeling. (Fig. 3).
Correlation of Lactate Labeling with Tumor Volume and MCT1 and
HIF1α Expression. The summed SNRLAC and LAC/PYR showed
significant correlations with tumor volume (R = 0.974, P < 0.001
and R = 0.903, P = 0.005, respectively; Fig. 2 A–C). The LAC/
PYR was also significantly correlated with the expression of
MCT1 on IHC (R = 0.85, P = 0.032), and the summed SNRLAC
was significantly correlated with MCT1 on RNA sequencing
(R = 0.907, P = 0.013; Fig. 2 D–G). HIF1α expression de-
termined by RNA sequencing was significantly correlated with
the LAC/PYR (R = 0.83, P = 0.043; Fig. 2 H and I). However, a
42-gene RNA-based hypoxia signature that had been developed
in breast cancer (30) did not correlate significantly with the LAC/
PYR (R = 0.39, P = 0.442) or summed SNRLAC (rho = 0.23, P =
0.658; Fig. 2 F–I). There were no significant correlations between
the LAC/PYR or summed SNRLAC and MCT4 expression,
where this was determined by IHC (rho = 0.54, P = 0.297 and
rho = 0.14, P = 0.803, respectively) or by RNA sequencing (R =
0.41, P = 0.420 and rho = −0.54, P = 0.297, respectively; SI
Appendix, Fig. S4 A–D), nor with the expression of LDHA de-
termined by RNA sequencing (R = 0.439, P = 0.383 and rho =
0.257, P = 0.658, respectively; SI Appendix, Fig. S4 E and F).
Correlation of 13C MRI with DCE-MRI. A significant correlation was
observed between ve and the LAC/PYR (R = 0.84, P = 0.035).
However, this correlation was driven mainly by one tumor
showing low ve and high LAC/PYR (SI Appendix, Fig. S3) and is
thus unlikely to be representative of the entire cohort. No other
significant correlations were observed between DCE parameters
(Ktrans, kep, ve, or iAUC90) and the LAC/PYR, summed SNRPYR,
and summed SNRLAC.
Discussion
Previous clinical studies have demonstrated 13C MRI with
hyperpolarized [1-13C]pyruvate in human prostate cancer and
in a range of brain tumors (7, 14, 15). Here we investigated the
metabolism of hyperpolarized [1-13C]pyruvate in breast cancer
patients and demonstrated the feasibility and safety of the
technique, as well as significant intertumoral metabolic hetero-
geneity. Hyperpolarized 13C-lactate signal was observed in the
summed spectra from all of the TNBCs and in all of the higher-
grade (G3) tumors, whereas there was no discernable hyper-
polarized 13C-lactate signal in the two lower-grade (G2) tumors.
This is consistent with previous preclinical studies in prostate
cancer, which have shown higher lactate signal in more-
aggressive tumors, and suggests that increased lactate label-
ing can be used as a biomarker for aggressive disease (11). In
addition, we observed intratumoral heterogeneity in lactate la-
beling in a single large triple-negative breast tumor, where the
level of lactate labeling was correlated with delivery of a gadolinium-
based contrast agent. Extensive preclinical studies have shown that
hyperpolarized 13C-pyruvate metabolism is frequently modulated
following treatment (31). The high levels of lactate labeling in
TNBC, which commonly undergo NAT, would make them suit-
able for response assessment using this technique.
Previous studies showing that intertumoral metabolic hetero-
geneity is more pronounced than intratumoral metabolic het-
erogeneity (32) and that core biopsy samples can be used to
reliably assess intertumoral differences (33–37) provided us with
a rationale for comparing global imaging-based metrics (mean
LAC/PYR and mean summed SNRLAC) with the results from
IHC and RNA sequencing of single tumor biopsies. The strong
correlation between the LAC/PYR with tumor volume, which is
known to correlate with hypoxia (38), led us to investigate the
contribution of hypoxia to the measured lactate signal. In tumors
with a high LAC/PYR, there was a significant increase in HIF1α
expression on RNA sequencing (R = 0.83, P = 0.043) (SI Ap-
pendix, Fig. S4), suggesting that hypoxia may account for the
correlation between LAC/PYR and tumor volume.
Metabolic reprogramming of cancer cells is often the down-
stream effect of oncogene activation or deletion of tumor sup-
pressor genes (39–41). MCT1, which imports pyruvate into cells,
and LDHA, which catalyzes hyperpolarized 13C label exchange
between the injected pyruvate and endogenous lactate pool,
can be up-regulated by the transcription factors HIF-1α and
c-Myc, either constitutively, such as following activation of the
Fig. 3. The 13C-pyruvate and 13C-lactate images acquired following i.v. injection of hyperpolarized [1-13C]pyruvate in a patient with TNBC. (A) Coronal T1 3D
spoiled gradient echo (SPGR) image. (B) Coronally reformatted DCE image at peak enhancement after i.v. injection of a gadolinium-based contrast agent. (C)
Summed hyperpolarized 13C-pyruvate and (D) summed hyperpolarized 13C-lactate images: area of low 13C-pyruvate and 13C-lactate signals in the center of the
tumor, likely corresponding to an area with low enhancement on DCE. (E) LAC/PYR map showing intratumoral heterogeneity (background removed by
thresholding). The dominant intratumoral heterogeneity was concordant between the DCE-MRI and HP 13C MRI images and represents decreased delivery of
both the gadolinium-based contrast agent and 13C-pyruvate to the center of the tumor. (F and G) Dynamic hyperpolarized 13C-pyruvate and 13C-lactate
images acquired over 15 time points after i.v. injection of hyperpolarized [1-13C]pyruvate (delay = 12 s; temporal resolution = 4 s).
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PI3K/Akt/mTOR pathway, or as a response to hypoxia (42). There
was a significant correlation between MCT1 protein expression and
HIF1α messenger RNA expression and tumors with high LAC/
PYR and summed SNRLAC. The expression of MCT1 is elevated
in glycolytic breast tumors, and high MCT1 expression predicts
poor prognosis (43). The correlation between the LAC/PYR and
the expression of MCT1, which, unlike MCT4, transports pyru-
vate in preference to lactate, can be explained by the influence of
pyruvate transport on the rate of exchange. A number of studies
have demonstrated that the tumor cell pyruvate transport can
have a significant influence on 13C label exchange and the ap-
parent exchange rate, including experiments on the effects of
pyruvate concentration (44), cell lysis (45), modulations of LDH
activity (45), and MCT1 inhibition (29), and a recent study in
prostate cancer patients which analyzed MCT1 expression (46).
Hyperpolarized 13C MRI was complementary to the DCE-MRI
measurements, with a correlation between kep and the summed
SNRPYR but no correlation between the other parameters de-
rived from the DCE-MRI and the hyperpolarized 13C magnetic
resonance spectroscopic imaging data. Since kep is related to
tissue perfusion, the correlation with summed SNRPYR is to be
expected. The lack of correlation between the other parameters
suggests that the hyperpolarized [1-13C]pyruvate experiment re-
flects other aspects of tumor biology that are not captured by
DCE-MRI. The combination of the two imaging strategies could
be exploited for early response assessment, where quantitative
DCE-MRI has demonstrated the potential to increase accuracy
in the prediction of pCR compared to standard clinical MRI, but
the results still depend on the molecular tumor subtype (47, 48).
Response assessment using proton magnetic resonance spec-
troscopy (1H-MRS) has proven challenging in the breast, due to
overlap of the lactate resonance with the intense lipid signals
from adipose tissue (49). A recent multicenter study on the
assessment of early treatment response in breast cancer using
1H-MRS showed very limited feasibility (50). Although uptake of
the glucose analog 18F-FDG imaged with positron emission to-
mography is widely used in oncological imaging for cancer de-
tection, staging, and response assessment, ionizing radiation
should ideally be minimized in women of reproductive age, and it
is not used routinely in the assessment of primary breast cancer.
In addition, it reflects cellular uptake via the glucose transporters
and phosphorylation by hexokinase, but it does not allow the
assessment of the downstream metabolism that can be probed
with hyperpolarized [1-13C]pyruvate.
This study, although in a relatively small cohort, demonstrates
the feasibility and safety of hyperpolarized 13C MRI in patients
with early breast cancer and that metrics obtained from 13C MRI
measurements of hyperpolarized [1-13C]pyruvate metabolism are
correlated with the molecular characteristics of the tumors. In-
creased hyperpolarized [1-13C]lactate signal in larger and more-
aggressive tumors appears to be driven by hypoxia, through
increased MCT1 expression.
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